114027
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
C 反应蛋白 - 白蛋白 - 淋巴细胞指数（CALLY）在 III 期乳腺癌患者中的临床预后价值
Authors Zhu M, Cheng R, Zhang K, Yue C, Guan S, Chen L, Wang J, Wang Y, Zhang B
Received 21 September 2025
Accepted for publication 2 December 2025
Published 22 December 2025 Volume 2025:17 Pages 1293—1305
DOI https://doi.org/10.2147/BCTT.S569199
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Seema Singh
Mengliu Zhu,1 Ran Cheng,1 Kaitong Zhang,1 Chaosen Yue,1 Shan Guan,1 Li Chen,2 Jing Wang,2 Yu Wang,1 Bing Zhang1
1Department of Breast Center, Beijing Tongren Hospital, Capital Medical University, Beijing, 100176, People’s Republic of China; 2Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital/Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of China
Correspondence: Yu Wang, Department of Breast Center, Beijing Tongren Hospital, Capital Medical University, Beijing, 100176, People’s Republic of China, Tel +8618911526337, Email wangyudayouxiang@126.com Bing Zhang, Department of Breast Center, Beijing Tongren Hospital, Capital Medical University, Beijing, 100176, People’s Republic of China, Tel +8618482105872, Email zhangbingdayou@126.com
Objective: To investigate the relationship between the C-reactive protein-albumin-lymphocyte index (CALLY) and clinicopathological characteristics, as well as its prognostic value in stage III breast cancer patients.
Methods: A retrospective analysis was conducted on the clinicopathological data of 187 stage III breast cancer patients who were treated in our hospital from 2010 to 2015. The optimal cut-off value for CALLY index was determined by ROC curve. Chi-square tests and Fisher’s exact tests were used for intergroup analysis. Survival curves were plotted using Kaplan-Meier method, and comparisons between groups were made using Log Rank test. Univariate and multivariate analyses were performed using the COX regression model. A nomogram prediction model was constructed based on the results of multivariate analysis and validated using the concordance index (C-index), calibration curves, and decision curve analysis (DCA).
Results: According to ROC curve, the optimal cut-off value for CALLY was determined to be 0.10, dividing the patients into a low CALLY group (54 patients) and a high CALLY group (133 patients). CALLY was identified as a potential independent prognostic factor for stage III breast cancer patients. Patients with high CALLY values had longer survival time than those with low CALLY values (DFS: χ2 = 9.109, P = 0.0025; OS: χ2 = 5.637, P = 0.0176). The C-indices for the nomograms predicting DFS and OS were 0.692 (95% CI: 0.541– 0.811) and 0.730 (95% CI: 0.586– 0.838), respectively. The calibration curves showed excellent calibration performance for predicting 1-year and 3-year DFS and OS. Decision curve analysis revealed that the nomogram model had better clinical performance than the CALLY model in predicting 3-year, 5-year, and 10-year DFS and OS.
Conclusion: CALLY index is a potential independent prognostic factor for stage III breast cancer patients. It provides new insights and methods for clinical diagnosis and treatment of breast cancer.
Keywords: breast cancer, CALLY, albumin, C-reactive protein, prognosis, nomogram
1Department of Breast Center, Beijing Tongren Hospital, Capital Medical University, Beijing, 100176, People’s Republic of China; 2Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital/Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of China
Correspondence: Yu Wang, Department of Breast Center, Beijing Tongren Hospital, Capital Medical University, Beijing, 100176, People’s Republic of China, Tel +8618911526337, Email wangyudayouxiang@126.com Bing Zhang, Department of Breast Center, Beijing Tongren Hospital, Capital Medical University, Beijing, 100176, People’s Republic of China, Tel +8618482105872, Email zhangbingdayou@126.com
Objective: To investigate the relationship between the C-reactive protein-albumin-lymphocyte index (CALLY) and clinicopathological characteristics, as well as its prognostic value in stage III breast cancer patients.
Methods: A retrospective analysis was conducted on the clinicopathological data of 187 stage III breast cancer patients who were treated in our hospital from 2010 to 2015. The optimal cut-off value for CALLY index was determined by ROC curve. Chi-square tests and Fisher’s exact tests were used for intergroup analysis. Survival curves were plotted using Kaplan-Meier method, and comparisons between groups were made using Log Rank test. Univariate and multivariate analyses were performed using the COX regression model. A nomogram prediction model was constructed based on the results of multivariate analysis and validated using the concordance index (C-index), calibration curves, and decision curve analysis (DCA).
Results: According to ROC curve, the optimal cut-off value for CALLY was determined to be 0.10, dividing the patients into a low CALLY group (54 patients) and a high CALLY group (133 patients). CALLY was identified as a potential independent prognostic factor for stage III breast cancer patients. Patients with high CALLY values had longer survival time than those with low CALLY values (DFS: χ2 = 9.109, P = 0.0025; OS: χ2 = 5.637, P = 0.0176). The C-indices for the nomograms predicting DFS and OS were 0.692 (95% CI: 0.541– 0.811) and 0.730 (95% CI: 0.586– 0.838), respectively. The calibration curves showed excellent calibration performance for predicting 1-year and 3-year DFS and OS. Decision curve analysis revealed that the nomogram model had better clinical performance than the CALLY model in predicting 3-year, 5-year, and 10-year DFS and OS.
Conclusion: CALLY index is a potential independent prognostic factor for stage III breast cancer patients. It provides new insights and methods for clinical diagnosis and treatment of breast cancer.
Keywords: breast cancer, CALLY, albumin, C-reactive protein, prognosis, nomogram